1.. Resource utility {#S1}
====================

We have engineered the ATOX1 exon 2 in a H1 human embryonic stem cell line to express mCherry-ATOX1 fusion proteins. This cell line can differentiate to different germ layers, which is useful for imaging-based studies on molecular mechanisms of ATOX1.

2.. Resource details {#S2}
====================

ATOX1 is an intracellular copper chaperone, a cell-cycle modulator, and a therapeutic cancer target ([@R1]; [@R3]; [@R4]). ATOX1 deficiency results in perturbed intracellular trafficking of copper transporters and altered cell proliferation during early development. ATOX1 is ubiquitously observed in different cells and tissues. However the detail intracellular molecular behaviors, such as subcellular distribution and interaction dynamics, of ATOX1 in response to environmental cues are still unclear. To dissect the roles of ATOX1 in different cell contexts under endogenous regulatory by using single-molecule super-resolution microscopy in live cell ([@R2]), here we genetically tagged ATOX1 with fluorescence protein in the H1 stem cell to generate the mCherry-ATOX1 knocked-in (H1_mCh-ATOX1, KI) clone.

We genetically modified H1 human embryonic stem cells (hESCs) by CRISPR-Cas9 mediated homologous recombination ([Fig. 1A](#F1){ref-type="fig"}). H1 hESCs were co-transfected with the single-guide RNAs (sgRNAs)-Cas9 containing plasmids together with corresponding recombination donor plasmids. After puromycin selection, the emerged hESC clones were picked and screened for mCherry insertion by Southern blotting ([Suppl. Fig. 1](#SD1){ref-type="supplementary-material"}) and DNA sequencing. We obtained a heterozygous mCherry-ATOX1 KI clone: One allele carries mCherry in-framed insertion upstream to the ATOX1 start codon, yet the other allele has a 51 bp deletion at −12 to the ATOX1 start codon and no mCherry insertion ([Fig. 1B](#F1){ref-type="fig"} & [Suppl. Fig. 2](#SD2){ref-type="supplementary-material"}). Nevertheless, the deletion has no overt impacts because the KI clone still grows normally and exhibits characteristic hESC morphology (i.e., densely packed cell clusters with well-defined borders, [Fig. 1C](#F1){ref-type="fig"}). This KI clone is free of mycoplasma contamination tested by PCR-based method ([Table 1](#T1){ref-type="table"}). Immunofluorescence staining demonstrated expression of pluripotency transcription factors NANOG, OCT3/4, and SOX2 in KI clone ([Fig. 1D](#F1){ref-type="fig"}). We further quantified the transcription of pluripotency genes, ATOX1, and mCherry by qRT-PCR ([Fig. 1E](#F1){ref-type="fig"}). Compared with the parental H1 hESCs, KI cells showed comparable expression of all three pluripotency genes (NANOG, 97 ± 3%; OCT4, 87 ± 6%; and SOX2, 107 ± 2%), but the level of ATOX1 transcript in KI clone was reduced (26 ± 1%). Despite the reduced transcript level, immunoblotting results against ATOX1 showed increased mCherry-ATOX1 protein level in the KI lysate compared to the endogenous ATOX1 in the parental H1 lysates ([Fig. 1F](#F1){ref-type="fig"}), probably due to improved protein stability. The un-tagged ATOX1, expected to be endogenous ATOX1 expressed from mCherry-null allele, was barely detectable in the KI hESC lysate, suggesting that endogenous ATOX1 was effectively knocked out in the mCherry-null allele. G-band karyotype analysis confirmed the normal karyotype of KI hESCs ([Fig. 1G](#F1){ref-type="fig"}). Histological staining of KI hESC-derived teratoma showed characteristics of epithelium (endoderm), cartilage (mesoderm), and melanin (ectoderm), confirming the differentiation capability of KI hESCs to three germ layers ([Fig. 1H](#F1){ref-type="fig"}). The short tandem repeat (STR) profile also confirmed that the KI cell still maintains its identity to the parental H1 hESCs (data available upon request). The characterization of KI hESCs is summarized in [Table 1](#T1){ref-type="table"}.

In summary, the fluorescence KI hESC clone is pluripotent and possesses normal karyotypes. With fluorescence protein mCherry directly tagged on ATOX1 whose expression is still controlled by endogenous regulatory machinery, KI hESCs enable imaging-based approaches to study the cell-type-specific function of ATOX1.

3.. Materials and methods {#S3}
=========================

3.1.. Cell culture {#S4}
------------------

H1 hESCs (NIH Registration Number: 043, WiCell, passage 28--30) were maintained in mTeSR™1/Matrigel™ feeder-free system at 37 °C with 5% CO2 until cells reach 80% confluent. Cells were genetically engineered via CRISPR/Cas9 mediated homologous recombination by co-electrotransfecting sgRNA-Cas9 plasmids and homology-direct recombination (HDR) donor plasmid. Transfected cells were plated on puromycin-resistant MEF feeders overnight followed by puromycin selection for four days. Clones were picked and seeded in plates under feeder-free culture system again then passaged for clonal expansion and characterization.

3.2.. CRISPR plasmid design {#S5}
---------------------------

We adopted the protocol from Ran et al. ([@R5]) and designed the sgRNAs using web tool from Benchling. The sgRNAs targeting to the upstream of ATOX1 coding region ([Table 2](#T2){ref-type="table"}) were cloned into the pSpCas9(BB)--2A-Puro (PX459) V2.0 plasmid (Addgene). A 3 kb genome region covering ATOX1 exon 2 (NC_000005.10, 151,757,164..151760261) were PCR amplified from H1 genome and cloned into pMiniT2 plasmid (NEB) as HDR arm. The mCherry sequence was PCR amplified and assembled into the donor plasmid by seamless cloning (NEB).

3.3.. PCR, sequencing, and str {#S6}
------------------------------

Genomic DNA was isolated from \~2 ×106 cells by using MasterPure™ Complete DNA and RNA Purification Kit (Epicentre). PCR was performed using primers ([Table 2](#T2){ref-type="table"}) and AccuStart™ II GelTrack PCR SuperMix (QuantaBio). PCR protocol: 95 °C for 3 min; 25 cycles of 95 °C for 30 s, 60 °C for 10 s, and 68 °C for 3.5 min; and 72 °C for 5 min. Sanger sequencing was performed by Eton Bioscience. STR DNA fingerprinting was done by the CCSG-funded Characterized Cell Line Core Facility (The University of Texas M.D. Anderson Cancer Center). The STRs at 8 loci were assessed.

3.4.. qRT-PCR {#S7}
-------------

Total RNA was isolated the same way as DNA. Two microgram of total RNA were converted to cDNA by using All-in-One RT MasterMix (Applied Biological Materials Inc). qPCR was performed using primers ([Table 2](#T2){ref-type="table"}) following the protocol of iQ SYBR Green Supermix (BioRad). Results were calculated using the ΔΔCT method and normalized to GAPDH expression.

3.5.. Immunoblotting and immunofluorescence staining {#S8}
----------------------------------------------------

An equal amount of total protein from cell lysate was resolved in a SDS-PAGE for immunoblotting analysis. For immunofluorescence staining, cells were fixed with 4% paraformaldehyde in PBS for 15 min, blocked and incubated with primary antibodies ([Table 2](#T2){ref-type="table"}) overnight at 4 °C, incubated with secondary antibodies, and counterstained with DAPI.

3.6.. Karyotyping {#S9}
-----------------

The cultures were harvested and G-banded using standard protocols. Clonal chromosomal changes identified by G-banding were described according to an International System for Human Cytogenetic Nomenclature ISCN (McGowan-Jordan & An, n.d.). Twenty metaphase chromosome spreads at 400 band resolution were analyzed.

3.7.. Teratoma assay {#S10}
--------------------

Cells grown under log-phase were dissociated and resuspended in 50% Matrigel/DMEM-F12. Immunodeficient NOD SCID mice (Charles River Laboratories) were injected subcutaneously with 2 × 107 cells in each flank and observed for palpable teratoma formation. After six weeks, teratomas were excised then fixed in 10% formalin (Sigma). Histology was analyzed using H&E staining.

3.8.. Mycoplasma testing {#S11}
------------------------

Mycoplasma detection was performed using PCR Mycoplasma Detection Kit (Applied Biological Materials Inc.) according to the instructions from manufacturer
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###### 

Characterization and validation.

  Classification                        Test                                        Result                                                                                           Data
  ------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------
  Morphology                            Photography                                 Normal                                                                                           [Fig. 1 panel C](#F1){ref-type="fig"}
  Phenotype                             Qualitative analysis: Immunocytochemistry   Positive staining for pluripotency factors NANOG, OCT3/4, and SOX2                               [Fig. 1 panel D](#F1){ref-type="fig"}
                                        Quantitative analysis: RT-qPCR              Comparable expression levels of NANOG, OCT3/4, and SOX2 compared with H1                         [Fig. 1 panel E](#F1){ref-type="fig"}
  Genotype                              Karyotype (G-banding) and resolution        46XY; Resolution 450--500                                                                        [Fig. 1 panel G](#F1){ref-type="fig"}
  Identity                              Microsatellite PCR (mPCR) OR                N/A                                                                                              N/A
                                        STR analysis                                8 sites tested; all sites match parental H1                                                      Data available with authors
  Mutation analysis (IF APPLICABLE)     Sequencing                                  Heterozygous insertion                                                                           [Fig. 1 panel B](#F1){ref-type="fig"} and [Supplementary figure 2](#SD2){ref-type="supplementary-material"}
                                        Southern Blot                               Tag insertion in one allele, small deletion in the other allele, no apparent off-target effect   [Supplementary figure 1](#SD1){ref-type="supplementary-material"}
  Microbiology and virology             Mycoplasma                                  Mycoplasma test shows negative                                                                   [Supplementary figure 3](#SD3){ref-type="supplementary-material"}
  Differentiation potential             Teratoma formation                          Differentiation to three germ layers confirmed by H&E staining                                   [Fig. 1 panel H](#F1){ref-type="fig"}
  Donor screening (OPTIONAL)            HIV 1 + 2 Hepatitis B, Hepatitis C          N/A                                                                                              N/A
  Genotype additional info (OPTIONAL)   Blood group genotyping                      N/A                                                                                              N/A
  HLA tissue typing                     N/A                                         N/A                                                                                              

###### 

Reagents details.

  -------------------------------------------------------- --------------------------------------------------- --------------- ---------------------------------------------------------------------
  Antibodies used for immunocytochemistry/immunoblotting                                                                       
                                                           Antibody                                            Dilution        Company Cat \# and RRID
                                                                                                                               
  Pluripotency Markers                                     Goat anti-NANOG                                     1:500 (ICC)     R&D Systems Cat\# AF1997 RRID: AB_355,097
                                                           Mouse anti-OCT3/4                                   1:250 (ICC)     Santa Cruz Biotechnology Cat\# sc-9081, RRID:AB_2,167,703
                                                           Goat anti-SOX2                                      1:250 (ICC)     Santa Cruz Biotechnology Cat\# sc-17,320, RRID:AB_2,286,684
  Characterization Markers                                 Rabbit anti-mCherry                                 1:500 (ICC)     Abcam Cat\# ab167453, RRID:AB_2,571,870
                                                                                                               1:1000 (IB)     
                                                           Rabbit anti-ATOX1                                   1:1000 (IB)     Abcam Cat\# ab154179 RRID:
                                                           Mouse anti- β Actin                                 1:2000 (IB)     Sigma-Aldrich Cat\# A5441, RRID:AB_476,744
  Secondary antibodies                                     Donkey anti-Goat IgG (Alexa Fluor488 conjugate)     1:1000 (ICC)    Jackson ImmunoResearch Labs Cat\# 705--545--003, RRID:AB_2,340,428
                                                           Donkey anti-Mouse IgG (Alexa Fluor488 conjugate)    1:1000 (ICC)    Thermo Fisher Scientific Cat\# A-21,202, RRID:AB_141,607
                                                           Donkey anti-Rabbit IgG (Alexa Fluor594 conjugate)   1:1000 (ICC)    Thermo Fisher Scientific Cat\# A-21,207, RRID:AB_141,637
                                                           Peroxidase-AffiniPure Goat Anti-Mouse IgG           1:10,000 (IB)   Jackson ImmunoResearch Labs Cat\# 115--035--003, RRID:AB_10,015,289
                                                           Peroxidase-AffiniPure Goat Anti-Rabbit IgG          1:10,000 (IB)   Jackson ImmunoResearch Labs Cat\# 111--035--045, RRID:AB_2,337,938
                                                                                                                               
  -------------------------------------------------------- --------------------------------------------------- --------------- ---------------------------------------------------------------------

  -------------------------------------- ----------------------------------------------------------------------------------------------------
  Unique stem cell lines identifier      WAe001-A-29
  Alternative names of stem cell lines   H1_mCh-ATOX1 (KI) / UHMCe002-A-29
  Institution                            University of Houston, Houston, TX, United States
  Contact information of distributor     Tai-Yen Chen (<tchen37@central.uh.edu>)
  Type of cell lines                     ESC
  Origin                                 Human embryonic stem cell line
  Additional origin info                 Age: N/ASex: Male Ethnicity if known: N/A
  Cell Source                            H1 hESCs
  Clonality                              Clonal
  Method of reprogramming                N/A
  Gene modification                      Yes
  Type of modification                   Transgene expression (fluorescence protein)
  Associated disease                     N/A
  Gene/locus                             5q33.1; ATOX1 exon 2
  Method of modification                 CRISPR
  Name of transgene or resistance        mCherry
  Inducible/constitutive system          N/A
  Date archived/stock date               5/18/2019
  Cell line repository/bank              <https://hpscreg.eu/cell-line/WAe001-A-29>
  Ethical approval                       Cell lines were used according to institutional guidelines. UTHealth approval number: SCRO--16--01
  -------------------------------------- ----------------------------------------------------------------------------------------------------
